Harvard Apparatus Regenerative Technology Shares to Begin Trading Today Under NASDAQ Ticker Symbol HART

HOLLISTON, Mass.--(BUSINESS WIRE)--Effective today, Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, has begun trading on the NASDAQ exchange under the ticker symbol HART after being spun off by Harvard Bioscience, Inc. Harvard Apparatus Regenerative Technology (HART) was created to bring the life-saving therapies pioneered at Harvard Bioscience to patients. HART’s regenerative technology has been used in ten successful human airway transplants to date. HART’s first therapeutic product, the InBreath TM Airway Transplant System, uses a synthetic plastic scaffold in the size and shape of the patient’s natural trachea that, prior to surgery, is seeded with the patient’s own bone marrow cells in a specialized bioreactor. Because the system uses the patient’s own bone marrow the body does not reject the new organ, making anti-rejection medications following this type of transplant unnecessary. The first two of these surgeries were “world firsts” and were published in The Lancet, one of the most respected peer-reviewed global medical journals.

Help employers find you! Check out all the jobs and post your resume.